Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of Xiaoer Feireqing granules for respiratory tract infection-induced childhood bronchial asthma attack
ChiCTR2100050969Phase 4Recruiting
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of xiaoerfeireqing in asthma (2 arms), sponsored by Shanghai Municipal Hospital of Traditional Chinese Medicine. Primary endpoint: Asthma attack control time/ratio. Started May 2021; status: recruiting.
02
Drugs
xiaoerfeireqing
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR2100050969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050969.